References
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
- Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97:946–52
- Adult Treatment Panel III. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. J Am Med Assoc 2001;285:2486–97
- Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625–9
- Stein EA. Identification and treatment of individuals at high risk of coronary heart disease. Am J Med 2002;112(Suppl 8A):3S–9S
- Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152–60
- Bullano MF, Wertz DA, Yang GW, et al. Effectiveness of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469–78
- Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251–64
- Bullano MF, Kamat S, Willey VJ, et al. Agreement between administrative claims and the medical record in identifying patients with a diagnosis of hypertension. Med Care 2006;44:486–90
- Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044–51
- McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238–44
- Pravachol [package insert]. Princeton (NJ): Bristol-Myers Squibb; December 2001
- Lescol, Lescol XL [package insert]. East Hanover (NJ): Novartis Pharmaceuticals; October 2001
- Mevacor [package insert]. West Point (PA): Merck & Co.; June 2002
- Long JS. Regression models for categorical and limited dependent variables. Sage Publication; 1997
- Zocor (simvastatin) Package Insert. Whitehouse Station, N.J. Merck & Co, Inc. August 2005. Accessed online September 1, at: http://www.zocor.com/zocor/shared/documents/english/pi.pdf
- Lipitor Package Insert. New York, NY: Pfizer; Revised 2007. Accessed online 1 March 2007 at: http://www.fda.gov/cder/foi/label/2007/020702s047lbl.pdf
- Haffner SM, Goldberg RB. New strategies for the treatment of diabetic dyslipidemia. Diabetes Care 2002;25:1237–9
- Anon. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–503
- Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
- Quilliam BJ, Perez HE, Andros V, et al. Quantifying the effect of applying the NCEP ATP III criteria in a managed care population treated with statin therapy. J Manag Care Pharmacol 2004;10:244–50
- Fox MK, Gandhi SK, Ohsfeldt RL. Examining titration patterns in rosuvastatin as compared to other statins in routine clinical practice. Presented at the American Managed Care Pharmacy Educational Conference, October 2006, Chicago (IL)
- Johansson S, Ming EE, Wallander MA, et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf 2006;15:454–61